Argen-X (1AE) - Total Liabilities
Based on the latest financial reports, Argen-X (1AE) has total liabilities worth €1.08 Billion EUR (≈ $1.26 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Argen-X (1AE) cash flow conversion to assess how effectively this company generates cash.
Argen-X - Total Liabilities Trend (2016–2024)
This chart illustrates how Argen-X's total liabilities have evolved over time, based on quarterly financial data. Check Argen-X liquidity resilience to evaluate the company's liquid asset resilience ratio.
Argen-X Competitors by Total Liabilities
The table below lists competitors of Argen-X ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Banco Santander Brasil SA ADR
NYSE:BSBR
|
USA | $1.14 Trillion |
|
Rockwell Automation Inc
NYSE:ROK
|
USA | $7.43 Billion |
|
Datadog Inc
NASDAQ:DDOG
|
USA | $2.91 Billion |
|
Roche Holding AG
SW:RO
|
Switzerland | CHF62.82 Billion |
|
Celestica Inc.
TO:CLS
|
Canada | CA$4.99 Billion |
|
Unimicron Technology Corp
TW:3037
|
Taiwan | NT$139.01 Billion |
|
Yum! Brands Inc
NYSE:YUM
|
USA | $15.52 Billion |
|
Bayer AG NA
XETRA:BAYN
|
Germany | €74.51 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Argen-X's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 1AE company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argen-X's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argen-X (2016–2024)
The table below shows the annual total liabilities of Argen-X from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €704.24 Million ≈ $823.33 Million |
+58.27% |
| 2023-12-31 | €444.95 Million ≈ $520.19 Million |
+38.80% |
| 2022-12-31 | €320.56 Million ≈ $374.77 Million |
+1.43% |
| 2021-12-31 | €316.05 Million ≈ $369.50 Million |
-35.93% |
| 2020-12-31 | €493.32 Million ≈ $576.74 Million |
+28.94% |
| 2019-12-31 | €382.59 Million ≈ $447.29 Million |
+854.98% |
| 2018-12-31 | €40.06 Million ≈ $46.84 Million |
+54.22% |
| 2017-12-31 | €25.98 Million ≈ $30.37 Million |
-38.73% |
| 2016-12-31 | €42.40 Million ≈ $49.57 Million |
-- |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more